Combined measurement of CA 15-3 with novel autoantibodies improves diagnostic accuracy for breast cancer

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 273-279

  Dong, Xuejun ^a   Yang, Mingfeng ^a   Sun, He ^a   Juan, Lü ^a   Zheng, Zhuan ^a   Li, Zhiguo ^a   Zhong, Li ^b,c  

^a ZHEJIANG UNIVERSITY   (China)

^b HEBEI UNIVERSITY   (China)

^c WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Autoantibody; Breast cancer; Early detection; Phage display; Tumor marker; Tumor associate antigen

Indexed keywords

AUTOANTIBODY; CA 15-3 ANTIGEN; COMPLEMENTARY DNA; FERRITIN; FERRITIN HEAVY CHAIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN F; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN F ANTIBODY; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; BACTERIOPHAGE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA LIBRARY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OPEN READING FRAME; PREDICTION; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; UPREGULATION;

EID: 84875716960     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S43122     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43-66.
2. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287-5312.
3. Hanash S. Disease proteomics. Nature. 2003;422(6928):226-232.
4. Belousov PV, Kuprash DV, Nedospasov SA, Shebzukhov YV. Autoantibodies to tumor-associated antigens as cancer biomarkers. Curr Mol Med. 2010;10(2):115-122.
5. Tan HT, Low J, Lim SG, Chung MC. Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 2009;276(23):6880-6904.
6. Desmetz C, Cortijo C, Mange A, Solassol J. Humoral response to cancer as a tool for biomarker discovery. J Proteomics. 2009;72(6): 982-988.
7. Finn OJ. Immune response as a biomarker for cancer detection and a lot more. N Engl J Med. 2005;353(12):1288-1290.
8. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A. 1995;92(25):11810-11813.
9. Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol. 2006;1(6):513-519.
10. Old LJ, Chen YT. New paths in human cancer serology. J Exp Med. 1998;187(8):1163-1167.
11. Minenkova O, Pucci A, Pavoni E, et al. Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients. Int J Cancer. 2003;106(4):534-544.
12. Lenner P, Wiklund F, Emdin SO, et al. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. Br J Cancer. 1999;79(5-6):927-932.
13. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000;60(7):1777-1788.
14. Kulic ́ A, Sirotkovic ́-Skerlev M, Jelisavac-Cosic ́ S, Herceg D, Kovac Z, Vrbanec D. Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients. Med Oncol. 2010;27(3):887-893.
15. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res. 1992;52(15):4168-4174.
16. Raedle J, Oremek G, Welker M, Roth WK, Caspary WF, Zeuzem S. p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. Pancreas. 1996;13(3):241-246.
17. Conroy SE, Sasieni PD, Fentiman I, Latchman DS. Autoantibodies to the 90 kDa heat shock protein and poor survival in breast cancer patients. Eur J Cancer. 1998;34(6):942-943.
18. Zhong L, Peng X, Hidalgo GE, Doherty DE, Stromberg AJ, Hirschowitz EA. Identification of circulating antibodies to tumor-associated proteins for combined use as markers of non-small cell lung cancer. Proteomics. 2004;4(4):1216-1225.
19. Altschul SF, Madden TL, Schäffer AA, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997;25(17):3389-3402.
20. Honoré B, Baandrup U, Vorum H. Heterogeneous nuclear ribonucleoproteins F and H/H' show differential expression in normal and selected cancer tissues. Exp Cell Res. 2004;294(1):199-209.
21. Shpyleva SI, Tryndyak VP, Kovalchuk O, et al. Role of ferritin alterations in human breast cancer cells. Breast Cancer Res Treat. 2011; 126(1):63-71.
22. Chapman C, Murray A, Chakrabarti J, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol. 2007;18(5): 868-873.
23. Sugita Y, Wada H, Fujita S, et al. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res. 2004;64(6): 2199-2204.
24. Scanlan MJ, Gout I, Gordon CM, et al. Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. Cancer Immun. 2001;1:4.
25. Qian F, Odunsi K, Blatt LM, et al. Tumor associated antigen recognition by autologous serum in patients with breast cancer. Int J Mol Med. 2005;15(1):137-144.
26. Jäger D, Stockert E, Güre AO, et al. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res. 2001;61(5):2055-2061.
27. Volkmann M, Sinn HP, Gaugel D, et al. Anti-p53 in breast cancer: concordance of different assay procedures and association with p53 antigen expression. Oncology. 2002;63(3):297-305.
28. Laessig D, Nagel D, Heinemann V, et al. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Anticancer Res. 2007;27(4A):1963-1968.
29. Lin HS, Talwar HS, Tarca AL, et al. Autoantibody approach for serum-based detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2396-2405.
30. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med. 2005;353(12):1224-1235.
31. Zhong L, Hidalgo GE, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Using protein microarray as a diagnostic assay for non-small cell lung cancer. Am J Respir Crit Care Med. 2005;172(10): 1308-1314.
32. Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med. 2000;161(2 Pt 1):589-594.